natgillin/translations-raw huggingface dataset:
The anti-FcRn antibody or binding fragment thereof according to claim 10, wherein the polymer is PEG, having a molecular weight in the range of from about 5 to about 50 kDa. 
Anti-FcRn antitijelo ili njegov fragment prema patentnom zahtjevu 5, naznačen time, što je polimer PEG, primjerice s molekularnom masom u rasponu od 5 do 50 kDa.
The method according to claim 1 or claim 7, wherein the infection is caused by a drug-resistant strain. 
Kombinacija za uporabu prema zahtjevima 5 ili 6, naznačena time što je infekcija uzrokovana sa sojem rezistentnim na lijek.
Other are possible. 
Mogući su i drugi.
The pressure drop created by the sealing material has to be sufficient to enable the pressure in the enclosing space to reach for example 4 bars or more, preferably more than 8 bars, most preferably 10 to 13 bars, at which pressure the foil member will punctured/brake and the coffee extract can be released. 
Pad tlaka koji je stvoren pomoću materijala za brtvljenje treba biti dovoljan da bi omogućio tlaku u prostoru koji obuhvaća čahuru postizanje, na primjer, 4 bara ili više, poželjno više od 8 bara, najpoželjnije 10 dO 13 bara, kod kojeg tlaka se element koji je načinjen od folije probije/pukne i ekstrakt kave se može osloboditi.
Preparation of the set-style yoghurt product: 
Datum objave europskog patenta:
The pharmaceutical composition according to claim 1, wherein said ACE-inhibitor is selected from the group consisting of captopril, enalapril, lisinopril, ramipril, and perindopril. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni ACE-inhibitor odabran iz skupine koju čine kaptopril, enalapril, lizinopril, ramipril 1 perindopril.
The tablet as claimed in claim 1, in which said disintegrating agent is selected from the group consisting of crospovidone, sodium croscarmellose, sodium starch glycolate and partly pregelatinized starch. 
Tableta prema zahtjevu 1, naznačena time, da su navedeni dezintegratori odabrani iz skupine koju čine krospovidon, natrij-kroskarmeloza, natrijev škrobni glikolat, djelomično predželatinizirani škrob i ostali.
A method for the treatment of percolate from waste, said method comprising the step of adding to said waste a polymer of the superabsorbent polyelectrolytic macromolecular type hydrogel in the dry state to absorb and retain percolate from waste for gelling of the percolate wherein the polymer of the superabsorbent polyelectrolytic macromolecular type hydrogel is in combination with a second component, which is suitable to absorb the gaseous phase produced by the waste, characterized in that, said second component being selected from the group that consists of a- cyclodextrins, B-cyclodextrins, and the amount of a- cyclodextrins or B-cyclodextrins, is variable between 0 and 20% by weight with respect to the weight of superabsorbent polymer. 
Postupak za obradu perkolata iz otpada, te navedeni postupak obuhvaća korak dodavanja u navedeni otpad polimera superapsorbirajućeg polielektrolitičkog makromolekularnog tipa hidrogela u suhom stanju da apsorbira i zadrži perkolat iz otpada za geliranje perkolata pri čemu je polimer superapsorbirajućeg polielektrolitičkog makromolekularnog tipa hidrogela u kombinaciji s drugom komponentom, koja je prikladna za apsorpciju plinovite faze proizvedene od strane otpada, naznačen time što je navedena druga komponenta odabrana iz skupine koja sadrži a-ciklodekstrine, B-ciklodekstrine, te količina a-ciklodekstrina ili B-ciklodekstrina, varira između 0 i 20 masenih % u odnosu na masu superapsorbirajućeg polimera.
The lithium accumulator of any of claims 1 to 3 wherein the active material is selected from the group consisting of mixed oxides or phosphates of lithium, manganese, chrome, vanadium, titanium, cobalt, aluminum, nickel, iron, lanthanum, niobium, boron, cerium, tantalum, tin, magnesium, yttrium and zirconium. 
Litijski akumulator prema bilo kojem od zahtjeva 1 do 3 u kojem je aktivni materijal odabran iz skupine koja se sastoji od miješanih oksida ili fosfata litija, mangana, kroma, vanadija, titana, kobalta, aluminija, nikla, željeza, lantana, niobija, bora, cerija, tantala, kositra, magnezija, itrija te cirkonija.
Composition for controlled ovarian stimulation 
SASTAV ZA KONTROLIRANU STIMULACIJU JAJNIKA
■ Degassing: Continuous 
Otplinjavanje: kontinuirano
ix a telomerase inhibitor, preferably telomestatin, a protease inhibitor, a matrix metalloproteinase inhibitor, a methionine aminopeptidase inhibitor, preferably bengamide or a derivative thereof, or a proteosome inhibitor, preferably PS-341, and/or 
inhibitor telomeraze, poželjno telomestatin; x. inhibitor proteaze, inhibitor metaloproteinaze matriksa, inhibitor aminopeptidaze metionina, poželjno bengamid ili njegov derivat, ili inhibitor proteozoma, poželjno PS-341, i/ili xi.
providing a sensor or an array of sensors comprising either: 
osiguravanja senzorskog čipa koji se nalazi u ili na sondi i sadrži:
a nucleic acid, DNA or RNA, coding for an antibody, or one of its functional fragments or derivatives, as claimed in one of claims 3-23, 26, 27, 30, 31 and 33-36; a nucleic acid comprising a DNA sequence selecting from the group of sequences consisting of: a nucleic sequence comprising the sequences SEQ ID No. 
Izolirana nukleinska kiselina, naznačena time da je odabrana od sljedećih nukleinskih kiselina: a) nukleinska kiselina, DNA ili RNA koja kodira antitijelo ili jedan od njegovih divaletnih fragmenata koji se veže na c-Met kao što je prijavljeno u patentnim zahtjevima 1 i 2, b) nukleinska kiselina koja sadrži sekvenciju DNA koja sadrži CDR-HI1 sekvenciju SEQ ID No.
A sensor assembly according to claim 9, wherein said second Bragg grating (1424) is provided as a moisture-sensing grating and said second longitudinal-strain-inducing jacket (1412C) is selected and configured to induce axial strain in said first optical fiber at said second Bragg grating as a function of presence of moisture. 
Senzoričko sklopovlje u skladu s patentnim zahtjevom 9, naznačeno time što je navedena druga Braggova rešetka (1424) postavljena kao rešetka za senzoriku vlage, a navedena druga obloga koja uzrokuje uzdužno naprezanje (1412C) je odabrana i konfigurirana da uzrokuje aksijalno naprezanje u navedenom prvom optičkom vlaknu kod navedene druge Braggove rešetke kao funkciju prisutnosti vlage.
(wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent. 
LAI 2 (pri čemu G predstavlja GIeNAc- ili GleNAc-Gal-) ili njihov inkluzijski spoj ciklodekstrina, i irimotekan kao protutumorsko sredstvo.
A neutralising antibody which binds human IL-17A and human IL-17F according to claim 1 or claim 7 which is cross-blocked from binding human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence given in SEQ ID NO:9 and the light chain sequence given in SEQ ID NO:7 and wherein the antibody is inhibited from binding to human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence given in SEQ ID NO:9 and the light chain sequence given in SEQ ID NO:7 by greater than 80% using competition ELISA or surface plasmon resonance. 
Antitijelo prema zahtjevu 1, pri čemu antitijelo obuhvaća teški lanac koji obuhvaća varijabilno područje teškog lanca koji se sastoji iz sekvence aminokiselina koja je prikazana u SEQ ID NO: 16 i konstantno područje teškog lanca koji je konstantno područje humanog gama-1 teškog lanca, i laki lanac koji obuhvaća varijabilno područje lakog lanca koji se sastoji iz sekvenci aminokiselina koje su prikazane u SEQ ID NO: 20 i konstantnog područja lakog lanca koji je konstantno područje humanog kapa lakog lanca.
The composition of claim 1, wherein the DNA-targeting RNA comprises one or more of: a phosphorothioate, an inverted polarity linkage, an abasic nucleoside linkage, a locked nucleic acid (LNA), a 2′-O-methoxyethyl modified sugar moiety, a 2′-O-methyl modified sugar moiety, a 2′-O-(2-methoxyethyl) modified sugar moiety, a 2′-fluoro modified sugar moiety, a 2′-dimethylaminooxyethoxy modified sugar moiety, a 2′-dimethylaminoethoxyethoxy modified sugar moiety, a peptide nucleic acid (PNA), a morpholino nucleic acid, and a cyclohexenyl nucleic acid (CeNA). 
Sastav prema bilo kojem od zahtjeva 1, ili 6 do 10, ili 12 do 13, ili postupak u skladu s bilo kojim od zahtjeva 2 do 4, ili 6 do 13, ili garnitura prema bilo kojem od zahtjeva 5 do 10, ili 12 do 13, naznačen/a time, da RNK koja cilja na DNK, obuhvaća jednu ili više modificiranih nukleobaza, modificiranih strukturnih okosnica ili ne-prirodnih internukleozidnih lančanih spojeva, modificirani dio molekule šećera, zaključanu nukleinsku kiselinu (LNA), ili peptidnu nukleinsku kiselinu.
The lid of this hive has to be taken off only when we have to work with the boards inside the hive. 
Poklopac ovce košnice sc mora skinuti samo kada se mora raditi s pločama unutar košnice.
reacting the compound of the formula (V) with 4-chloro-3-trifluoromethyl-phenyl isocyanate to give the compound of the formula (II). 
reakcijom spoja s formulom (V) s 4-kloro-3-trifluorometil-fenil izocijanatom da se dobije spoj s formulom (II).
1, a rock bolt 7 in accordance with the present invention is shown. The by a pressure media expandable rock bolt 7 comprises a connection unit for connection both of an expansion means 10 (see FIG. 2) and for connection of a suspension element 16 (see FIG. 
Rcfcrirajući sc sada na Sliku 1, prikazano je sidro u stijeni u skladu s predmetnim izumom. Sidro u stijeni 7, koje može ekspandirati pomoću tlačnog medija, sadrži veznu jedinicu za povezivanje i ekspanzionog sredstva 10 (vidi Sliku 2) i za povezivanje ovjesnog elementa 16 (vidi Sliku 3).
The method of claim 1, wherein the subject has diarrhea and constipation. 
u postupku liječenja konstipacije pri čemu subjekt ima konstipaciju bez dijareje
the composition is either free of phosphate buffering agents or comprises a phosphate buffer system in a concentration of at most 0.1 mM. 
• je bez fosfatnih pufera ili sadrži sustav fosfatnog pufera u koncentraciji najviše od 0.1 mM;
A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegovu farmaceutski prihvatljivu sol ili njegov solvat 1 farmaceutski prihvatljiv nosač.
The method of claim 2, wherein, the motor delivers torque and the method further comprises, reducing the flux excitation command signal during start-up of the system, to thereby reduce loading on the engine. 
4. - Postupak u skladu s patentnim zahtjevom 2 ili patentnim zahtjevom 3, naznačen time što motor (16) daje zakretni moment, te što postupak dodatno uključuje smanjivanje zapovjednog signala za pobudu fluksa prilikom pokretanja sustava kako bi se time smanjilo opterećenje na motoru (12).
According to a final aspect, the reactor of the invention herein is provided with support means, arranged on the outer surface of the housing of the reactor, adapted to bear the weight thereof, enabling the expansion of the reactor vertically and lateral damping means that prevent horizontal displacement. 
Reaktor u skladu s patentnim zahtjevom 1, naznačen time što ima nosač, smješten na vanjskoj površini kućišta reaktora, prilagođen za nošenje njegove težine, što omogućuje širenje reaktora u okomitom smjeru i bočni prigušivač koji sprječava vodoravno pomicanje.
The characteristics and symptoms of the disease include personality changes, depression, mood swings, unsteady gait, involuntary chorea, twitching and jerking movements and tremors, dementia, slurred speech, impaired judgement, difficulty in swallowing and an intoxicated appearance. 
Karakteristike i simptomi bolesti uključuju promjene osobnosti, depresiju, nagle i izmjenične promjene raspoloženja, nestabilan hod, nchotičnu koreju, pokrete trzanja i grčevitog trzanja te drhtanje, demenciju, nerazumljiv govor, nepravilno rasuđivanje, teškoće u gutanju i pijani izgled.
The expression vector according to claim 7, comprising a nucleotide sequence depicted in SEQ ID NO 89, or its conservative sequence variant. 
Ekspresijski vektor prema zahtjevu 7, koji sadrži sekvencu nukleotida prikazanu u SEQ ID NO 89 i njenu konzervativnu varijantu sekvence.
thereby giving, after reduction of the imine, and upon optional deprotection, a compound of formula (A), (B) or (C), as defined in claim 1 . 
O H (B6) te se tako dobiva, nakon redukcije imina, te nakon proizvoljnog uklanjanja zaštite, spoj s formulom (B), kako je definirano u zahtjevu 1.
validating the batch for distribution only if the sample of the batch after stability testing contains not more than a total of 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of the oxidation decomposition products of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide. 
Postupak za validaciju šarže N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamida ili njegove soli za distribuciju, naznačen time, da obuhvaća: a) podvrgavanje uzorka šarže ispitivanju stabilnosti; b) određivanje ukupne količine produkta oksidacijskog raspadanja u uzorku šarže nakon ispitivanja stabilnosti: 1
A solution of 0.5 mM EDTA/PBS (Ca++ Mg++ free) is added to the plate which is then incubated at 37° C. for 10 min. Cells are dislodged by gentle rapping of the flasks. 
Na ploča je dodana otopina 0,5 mM EDTA/PBS (bez Ca** i Mg"), te je ploča zatim inkubirana 10 minuta na 37 "C. Stanice su odvojene blagim lupkanjem tikvica.
The metered dose valve is generally spring loaded so that it returns to the closed position when finger pressure is released. 
Ventil za odmjeravanje doze je općenito pritisnut s oprugom tako da se on vraća u zatvoren položaj kad se prestane djelovati s pritiskom prsta.
According to a preferred embodiment, said sulphated amino acid is selected from: 1-methionine, 1-cysteine, 1-cystine, taurine, 4-thiazolidinecarboxylic acid, carboximethylcisteine and/or methylsulphonylmethane, or a physiologically acceptable salt thereof. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što komponentu a) se bira između 1-metionina, 1- cistein, 1-cistina, taurina, 4-tiazolidinkarboksilne kiseline, karboksimetilcisteina i/ili metilsulfonilmetana, ili njihovih fiziološki prihvatljivih soli.
In other embodiments, R2 is a 5-6 membered heteroaryl ring having 1-2 nitrogen atoms. 
(ii) - 5-6-eročlani heteroarilni prsten s 1-2 atoma dušika;
The T cell activating bispecific antigen-binding molecule of claim 21, wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor and/or reduce effector function. 
Bispecifična molekula vezana na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačena time, da Fc domena sadrži jednu ili više aminokiselinskih supstitucija koje smanjuju vezanje na Fc receptor, osobito FcY receptor, i/ili efektorsku funkciju, osobito stanično posredovanu citotoksičnost ovisnu o protutijelima (ADCC).
The synthesis may be performed in accordance to methods known in the art, e.g. in solution or by solid phase synthesis, starting with the first amino acid. 
Sinteza se može provesti u skladu s postupcima poznatim u struci, na primjer kao sinteza u otopini ili u krutoj fazi, započinjući s prvom amino kiselinom.
The formulation of anyone of claims 1 to 5 wherein the salt in the pH buffered saline solution is sodium chloride. 
Formulacija u skladu s patentnim zahtjevom 6, naznačena time što je sol u fiziološkoj otopini s puferiranim pH natrijev klorid.
The method according to Paragraph 1, wherein the one or more compounds are in the form of a pharmaceutically acceptable salt chosen from hydrochloride salt, hydrogen sulfate salt, sulfate salt, p-toluenesulfonyl salt, methansulfonyl salt and mixtures thereof. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što su jedan ili više spojeva u obliku farmaceutski prihvaljive soli, koju se bira između hidrokloridne soli, hidrogensulfatne soli, sulfatne soli, ptoluensulfonatne soli, metansulfonatne soli i njihovih smjesa.
The method of claim 1, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO:15 and the VL comprises the amino acid sequence set forth in SEQ ID NO:22. 
Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1, naznačeno time što sadrži VH slijed SEQ ID NO:15 i VL slijed SEQ ID NO:22; ili
a replacement of 90-100% of the endogenous mouse heavy chain variable region gene locus with a plurality of human heavy chain variable region gene segments, wherein the human heavy chain variable region gene segments are operably linked to an endogenous mouse heavy chain constant gene, and the human heavy chain variable region gene segments are capable of rearranging and forming a rearranged human/mouse chimeric heavy chain gene. The mouse of claim 1, wherein: 
zamjenu 90-100 % nepreuređenih mišjih segmenata gena VH s najmanje jednim nepreuređenim humanim segmentom gena VH i zamjenu svih endogenih mišjih segmenata gena D i JH s najmanje jednim nepreuređenim humanim segmentom gena D i najmanje jednim nepreuređenim ljudskim segmentom gena JH, pri čemu su humani segmenti gena VH, D i JH operativno povezani s endogenim mišjim konstantnim genom mišjeg teškog lanca, a humani segmenti gena VH, D i JH posjeduju sposobnost preuređivanja i formiranje preuređenog humanog/mišjeg kimernog gena teškog lanca.
Said watering is carried out over a period of preferably several days, in particular over a period of more than two days, in particular over a period of two to three days. 
Poželjno je da se navedeno namakanje izvodi kroz razdoblje od nekoliko dana, naročito kroz razdoblje od više od dva dana, naročito kroz razdoblje od dva do tri dana.
The method of claim 6, wherein said controlled milling effect comprises a controlled vibratory effect on the loaded bar stock generated by the clearance related harmonic level. 
Postupak sukladno zahtjevu 5, pri čemu, kontrolirani učinak mljevenja materijala obuhvaća kontrolirani vibratorni učinak na umetnuti materijal generiran harmoničnom razinom nastalom uvođenjem razmaka.
The mixture was then granulated by the addition of about 900 ml water whilst continuing to blend using both the impeller (300 rpm) and the chopper (speed II). 
Smjesa se zatim granulira dodatkom oko 900 ml vode, uz nastavak miješanja upotrebom i pokretača (300 okr/min) i vibratora (brzina II).
Due to digestion of fibres present in the basic formulation, short chain fatty acids are produced which lower the pH in the colon. 
Zahvaljujući probavi vlakana prisutnih u osnovnoj formulaciji, stvaraju se kratkolančane masne kiseline koje snizuju pH u debelom crijevu.
iv) compacting the mixture obtained in step iii), 
za podmazivanje; iv) zbijanje smjese dobivene u koraku iii),
A PRRS virus according to claim 1, wherein said PRRS virus has an RNA nucleotide sequence that corresponds to the DNA sequence set forth in either SEQ ID NO:1 or SEQ ID NO:10. 
PRRS-virus, naznačen time, da ima nukleotidnu sekvencu koja je najmanje 95% homologna sa sekvencom prikazanom u bilo kojoj od SEQ ID NO:1 ili SEQ ID NO:10.
A sterile, single use container, comprising the composition of claim 1 or claim 2. 
Sterilna, posuda za jednokratnu uporabu, obuhvaća smjesu iz patentnog zahtjeva 1 ili iz patentnog zahtjeva 2.
reacting said 9-carboxaldehyde substituted minocycline compound from step a) under palladium catalyzed coupling conditions, hydrogenolysis conditions or reductive amination conditions to generate said 9-substituted minocycline compound of said formula. 
reakciji navedenog 9-karbaldehidno supstituiranog minociklinskog spoja iz koraka a), u uvjetima paladijem katalizirane kondenzacije, uvjetima hidrogenolize ili uvjetima reduktivne aminacije, kako bi se dobilo navedeni 9-supstituirani minociklinski spoj navedene formule.
An assembly according to any of claims 1 to 4, in which the assembly comprises fluid guide means (14) for guiding the first and second fluid, the fluid guide means comprising a generally cylindrical guide member (14), which extends around the fluid contact arrangement, the cylindrical guide member comprising inner and outer skins (26, 28), the second fluid pathway extending between the inner and outer skins. 
Sklop temeljem bilo kojeg od zahtjeva 1 do 4, u kojem sklop uključuje način usmjeravanja fluida (14) za vođenje prvog i drugog fluida, s time da način usmjeravanja fluida uključuje općenito cilindrični dio za usmjeravanje (14), koji se proteže oko rasporeda za kontakt fluida, koji cilindrični dio za usmjeravanje se sastoji od unutarnjeg i vanjskog omotača (26, 28), a drugi prolaz za fluide se proteže između unutarnjeg i vanjskog omotača.
The method of claim 13, wherein the boat is selected to have a plurality of engines and a plurality of electronic controls, and wherein the method further comprises connecting the receiver to each of said electronic controls, wherein said plurality of engines can be controlled by a signal from the receiver. 
7. Metoda u skladu sa zahtjevom 6, naznačen time da plovilo ima više motora i više elektroničkih kontrola, te pri čemu metoda nadalje obuhvaća spajanje odašiljača na svaku od spomenutih elektroničkih kontrola, pri čemu se skupom spomenutih motora može upravljati signalom iz odašiljača.
mm long anti scatter shield: 
15 mm dugi štit protiv raspršenja:
wherein the receptor is a mammalian or human nuclear hormone receptor selected from the group consisting of an estrogen receptor, a progesterone receptor, a glucocorticoid receptor, an androgen receptor and mutant ER(T2) estrogen receptor as defined in SEQ ID NO: 80. 
gdje receptor jest nuklearni hormonski receptor od sisavca ili humani, izabran iz grupe koja obuhvaća Estrogenski receptor, progesteronski receptor, glukokortikoidni receptor, androgeni receptor i mutant ER(T2) Estrogenskog receptora definirano u SEQ ID NO: 80.
A tire cooling system (10), comprising: a tire support device (11) according to any one of claims 1 to 5; and 
Sustav za hlađenje guma (10), naznačen time, da sadržava: uređaj za pridržavanje gume (11) u skladu s bilo kojim od patentnih zahtjeva 1 do 5;
A non-transitory computer-readable medium for determining an association among IoT devices includes at least one instruction to receive, at a first IoT device, an identifier of a second IoT device, at least one instruction to obtain, by the first IoT device, a schema of the second IoT device based on the identifier of the second IoT device, and at least one instruction to determine, by the first IoT device, whether or not there is an association between the first IoT device and the second IoT device based on a schema of the first IoT device and the schema of the second IoT device, wherein the schema of the first IoT device comprises schema elements and corresponding values of the first IoT device and the schema of the second IoT device comprises schema elements and corresponding values of the second IoT device. BRIEF DESCRIPTION OF THE DRAWINGS 
Postupak za određivanje asocijacije između IoT (/nternet-of-Things) uređaja, IoT uređaja, sadrži: prijam (960) identifikatora drugog IoT uređaja, na strani prvog IoT uređaja; preuzimanje (970) sheme drugog IoT uređaja od strane prvog IoT uređaja, a na osnovu identifikatora drugog IoT uređaja; određivanje (980) na strani prvog IoT uređaja da li postoji ili ne postoji asocijacija između prvog IoT uređaja i drugog IoT uređaja, a na osnovu sheme prvog IoT uređaja i sheme drugog IoT uređaja, gdje shema prvog IoT uređaja sadrži elemente sheme i njima pripadajuće vrijednosti prvog IoT uređaja 1 gdje shema drugog IoT uređaja sadrži elemente sheme 1 njima pripadajuće vrijednosti drugog IoT uređaja.
A further aim of the invention is to provide a drink dispenser assembly with which the container with carbonated drink therein can be connected in a simple, rapid and reliable manner to a pressure medium reservoir by inexperienced users. 
Daljnji cilj izuma je ostvariti sustav raspršivača pića pomoću kojeg će se moći spojiti spremnik s gaziranim pićem i tlačnim spremnikom medija na jednostavan, brz i pouzdan način od strane korisnika bez iskustva.